On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first disclosure of NP1867; a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2. We showed, for the first time, that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.
To download the poster please submit the form below.